**SSC Subcommittee Project/Collaborative Project**

All future projects must complete a one-page document stating the following:

- **Name of the Project**: International registry on the use of the direct oral anticoagulants for the treatment of unusual site VTE

- **Person responsible (Chair / Principal Investigator)**: Nicoletta Riva and Walter Ageno

- **Aim / Mandate of the project**: to evaluate the rationale for the use of direct oral anticoagulants (DOACs) for the treatment of venous thrombosis occurring in unusual sites (i.e. with the exclusion of thrombosis of the upper limbs, lower limbs and pulmonary arteries) in real life clinical practice, and to assess the safety and effectiveness of this approach

- **Methodology (in very brief, not more than 1 paragraph)**: It is a multicenter, international, observational study of patients with objective diagnosis of thrombosis in unusual sites (inclusive, but not limited to splanchnic vein thrombosis, cerebral vein thrombosis, retinal vein thrombosis, ovarian vein thrombosis, upper and lower caval vein thrombosis, renal vein thrombosis) treated with one of the DOACs. Information will be collected on baseline characteristics, risk factors for thrombosis, timing of initiation of the DOAC with respect to the onset of symptoms and/or objective diagnosis, use of other anticoagulants prior to the DOACs, reasons for starting the DOAC or switching to the DOAC, occurrence of thrombotic events (arterial or venous thrombosis), major bleeding events (according to ISTH definition), and mortality during follow up. A minimum follow up of 6 months (maximum 12 months) is requested for each patient.

- **Inclusion / recruitment criteria (if applicable)**: consecutive adult (≥18 years) patients with objectively diagnosed venous thrombosis (between the years 2017 and 2021) not involving the upper limbs, lower limbs and pulmonary arteries and treated with one of the DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this study. Retrospective cases will be accepted if patients are prospectively followed up by the participating centers and all requested information is available.

Patients enrolled in other interventional studies evaluating the DOACs for the treatment of thrombosis in unusual sites will be excluded.

- **Year of starting**: 2018 (Q3)

- **Annual report of project**: yes

- **Year of completion (expected)**: 2022